If you searched “retatrutide before and after,” you were probably hoping to see dramatic transformation photos — a grid of side-by-side images promising a specific result. This page does not have those, and that is a deliberate choice. We do not publish transformation photos, testimonials, or promised outcomes for research compounds, because those images are unverifiable and, for a research-use-only material, misleading. What we can do is show you what the actual peer-reviewed research has measured over time. That is a more honest “before and after” than any photo.
Retatrutide (development code LY3437943) is an investigational “triple agonist” — a single peptide that activates the GIP, GLP-1, and glucagon receptors. It is being developed by Eli Lilly and is not an approved medicine for weight loss or any other use at the time of writing. Everything below comes from clinical trials, not from anecdotes or our own products.
What the research shows over time
The most informative human data come from three clinical (not preclinical, not anecdotal) phase 2 randomized, placebo-controlled trials, all sponsored by the manufacturer. They measured different endpoints — body weight, blood sugar, and liver fat — over 24 to 48 weeks. The consistent theme is that measured changes are gradual and dose-dependent, accumulating over months rather than appearing quickly.
In the pivotal obesity trial, the primary endpoint was the percentage change in body weight at 24 weeks, with participants followed to 48 weeks. Weight continued to decline throughout, and at the highest dose the average change was still trending downward at week 48 (Jastreboff et al., 2023).
| Study (year, journal) | Population & duration | What was measured | Key measured outcome (highest dose vs. placebo) |
|---|---|---|---|
| Jastreboff et al., 2023 — NEJM (phase 2 RCT, NCT04881760) | 338 adults with obesity/overweight; 48 weeks | % body-weight change | −24.2% at 48 weeks (12 mg) vs −2.1% placebo; ≥15% weight reduction in 83% of the 12 mg group vs 2% placebo |
| Rosenstock et al., 2023 — Lancet (phase 2 RCT, NCT04867785) | 281 adults with type 2 diabetes; up to 36 weeks | HbA1c (blood sugar) + body weight | HbA1c −2.02% at 24 weeks (12 mg) vs −0.01% placebo; body weight −16.9% at 36 weeks |
| Sanyal et al., 2024 — Nature Medicine (phase 2a substudy, NCT04881760) | 98 adults with fatty-liver disease (MASLD); 24 weeks | Liver-fat content (imaging) | Liver fat −82.4% at 24 weeks (12 mg) vs +0.3% placebo; normal liver fat (<5%) reached by 86% at 12 mg vs 0% placebo |
A few honest caveats about this table. Every one of these is a phase 2 study — meaning the drug’s efficacy and full safety profile are still being confirmed. Large phase 3 trials, including cardiovascular-outcome studies, are ongoing and had not reported results as of mid-2026 (ClinicalTrials.gov NCT05882045; a head-to-head trial versus tirzepatide, NCT06662383). Everything you read online claiming a definitive “final” result on retatrutide is running ahead of the published evidence.
Realistic expectations
Here is what the data does support: in supervised trials, retatrutide produced substantial, dose-dependent reductions in body weight and liver fat over several months. Here is what it does not support: any specific promise for an individual. Trial results are group averages, and the spread between people was wide. Participants also received careful medical supervision, a slow dose-escalation schedule, and a defined pharmaceutical-grade formulation — none of which is guaranteed by material bought as a research chemical.
This is exactly why online “before and after” photos are unreliable for a compound like this. Such images cannot verify the identity or purity of what was actually used, the dose, the timeframe, concurrent diet or other drugs, or whether the photo was edited. A research-use-only material is not the clinically studied product, so attaching trial-sized expectations to it is not scientifically justified.
Safety & legal status
The trials did document a consistent safety signal. The most common adverse events were gastrointestinal — nausea, diarrhea, vomiting, and constipation — which were dose-related and mostly mild to moderate, and were reduced by starting at a lower dose (Jastreboff et al., 2023). A dose-dependent increase in heart rate was observed, peaking around 24 weeks before declining, on the order of a few beats per minute (Jastreboff et al., 2023; Doggrell, 2023). In the diabetes trial, there were no reports of severe hypoglycemia and no deaths (Rosenstock et al., 2023).
On legal status: retatrutide is an investigational compound that is not approved by the FDA or other major regulators for weight loss, diabetes, or any other indication. Products referenced on this site are sold strictly for laboratory research use only — not for human consumption, and not as a treatment. Nothing here is medical advice.
Dosage reference
If you are documenting research handling and reconstitution, our Retatrutide dosage chart lays out the concentrations and volumes used in the published dose ranges. To convert a target dose into a syringe volume for a given vial and reconstitution, use our peptide dosage calculator. These are reference tools for research contexts only and do not imply any human use.
FAQ
Are there real before/after photos of retatrutide?
There is no verified, published set of “before and after” photos, and we do not host any. The genuine record is data: measured percentage changes in weight, liver fat, and blood sugar from randomized trials (Jastreboff et al., 2023; Sanyal et al., 2024). Photos circulating online cannot confirm what was used, the dose, or the timeline, so they should not be treated as evidence.
How long until changes appeared in the studies?
Slowly and steadily. The obesity trial measured its primary endpoint at 24 weeks and kept following participants to 48 weeks, with average weight still declining at the highest dose by the end (Jastreboff et al., 2023). Liver-fat reductions were measured over 24 weeks (Sanyal et al., 2024). These are multi-month changes on a supervised, escalating schedule — not overnight results.
Is retatrutide proven and approved?
Not yet. The published evidence is phase 2. Larger phase 3 trials — including long-term cardiovascular-outcome studies — were still ongoing and unreported as of mid-2026 (ClinicalTrials.gov NCT05882045; NCT06662383). It remains an investigational, research-use-only compound and is not an approved product for any use described above.
